Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
Dexcom Inc (DXCM) is a leader in continuous glucose monitoring systems, transforming diabetes care through real-time health data solutions. This page consolidates official announcements, financial updates, and strategic developments for stakeholders tracking the company’s progress in medical technology.
Access timely updates on product innovations, regulatory milestones, and partnership agreements that shape Dexcom’s position in the diabetes management sector. Investors will find earnings reports and market analyses, while healthcare professionals can monitor clinical trial outcomes and device enhancements.
Key content includes FDA clearances, international expansion updates, and technology integration developments with insulin delivery systems. All materials are sourced from verified channels to ensure reliability for research and decision-making.
Bookmark this page for streamlined access to Dexcom’s latest advancements in CGM technology and related financial performance. Check regularly for critical updates that impact both patient care and investment considerations.
Dexcom (NASDAQ:DXCM), a leader in glucose biosensing, will present significant innovations and clinical evidence at the 61st EASD Conference. The company will introduce Dexcom Smart Basal, a new integrated titration module currently under FDA and CE mark review, designed to simplify basal insulin management.
Key clinical findings include: reduced neonatal complications in gestational diabetes using CGM versus fingersticks, optimized glucose control through exercise timing in pregnant Type 1 diabetes patients, and a 65% reduction in hypoglycemic events when switching from fingersticks to Dexcom CGM. New cost-effectiveness data from Japan demonstrates CGM's superiority over fingersticks for Type 2 diabetes patients on insulin therapy.
Dexcom (NASDAQ:DXCM), the global leader in glucose biosensing, has launched its first open call for diabetes advocates in the U.S. and Canada. The initiative invites individuals aged 2 and older living with all types of diabetes and prediabetes to apply through September 19, 2025, for a chance to be featured in Dexcom's 2025 World Diabetes Day campaign.
Selected candidates will participate in a Los Angeles photoshoot and receive ongoing support from Dexcom throughout the year to attend events and connect with the diabetes community. The campaign is supported by Nick Jonas, multi-platinum recording artist and diabetes advocate. Applications can be submitted at Dexcom.com/WorldDiabetesDay until September 19 at 12 p.m. PDT.
Dexcom (NASDAQ:DXCM), a leading medical device company, has announced its participation in two upcoming investor conferences. The company's management will present at the 2025 Wells Fargo Healthcare Conference on September 3, 2025, at 2:15 PM EDT, and at the Baird 2025 Global Healthcare Conference on September 10, 2025, at 2:00 PM EDT.
Investors can access the webcasts through Dexcom's investor relations website at investors.dexcom.com, where recordings will also be archived for future viewing.
Synchron, a brain-computer interface (BCI) company, has strengthened its executive team with two significant appointments. Andy Rasdal, former DexCom (NASDAQ: DXCM) CEO, joins as Chief of Staff while continuing his Board position, and Mark Brister takes the role of VP R&D.
Rasdal brings over 30 years of medical device industry experience, notably leading DexCom through FDA approval and IPO, and previously serving as President of Medtronic Vascular. Brister contributes 38 years of experience in medical device technologies, with over 450 patents and involvement in launching more than 100 products.
These appointments aim to advance Synchron's Stentrode® BCI through U.S. clinical trials and prepare for global market entry, potentially transforming treatment for millions with motor impairment.
Dexcom (NASDAQ:DXCM) reported strong Q2 2025 financial results with revenue growing 15% year-over-year to $1.157 billion. The company achieved GAAP operating income of $212.6 million, representing 18.4% of revenue. Dexcom also announced a CEO succession plan, with Jake Leach set to become CEO effective January 1, 2026, while current CEO Kevin Sayer will transition to executive chairman.
Key highlights include FDA clearance for the Dexcom G7 15 Day CGM System, launch of AI-based Smart Food Logging, and enhanced Stelo customer experience. The company raised its 2025 revenue guidance to $4.600-$4.625 billion (14-15% growth) while maintaining guidance for other metrics, including Non-GAAP Operating Margin of approximately 21%.
The company maintains a strong financial position with $2.93 billion in cash, cash equivalents, and marketable securities.Dexcom (NASDAQ: DXCM) announced the expansion of coverage for its Dexcom G7 Continuous Glucose Monitoring (CGM) System under Ontario's Drug Benefit (ODB) program. The coverage now extends to eligible Ontarians managing diabetes with insulin, impacting a significant portion of the estimated 1.7 million people living with diabetes in Ontario.
The Dexcom G7, recognized as the most accurate CGM and the #1 preferred glucose sensor by Canadian endocrinologists, offers unique features including a predictive urgent low alert, waterproof sensor, 30-minute warm-up time, and direct Apple Watch functionality. The expanded coverage makes Dexcom G7 the most covered CGM on government-funded programs in Ontario, available through ODB, ADP, private insurance, and NIHB programs.
Dexcom (NASDAQ:DXCM), the global leader in glucose biosensing, has launched a groundbreaking AI-powered Smart Food Logging feature across its product portfolio. The feature is now available on both Stelo, the first FDA-cleared over-the-counter glucose biosensor, and Dexcom G7, making it the only prescription continuous glucose monitor in the U.S. with photo logging capability.
The innovative feature allows users to simply take a photo of their food in the app, where AI automatically identifies ingredients and populates meal descriptions. This launch is accompanied by several other technological enhancements, including Weekly Insights powered by GenAI, Oura integration for holistic biometric tracking, customizable target ranges in Dexcom G7, and a new Glucose Impact feature for better understanding of how various activities affect glucose levels.
Users can access these features by updating to the latest version of their respective apps on iOS and Android platforms.Dexcom (NASDAQ:DXCM) has announced the fourth season of its groundbreaking Dexcom U NIL program, exclusively for college athletes with diabetes. The 2025 roster features 21 total athletes, including 13 new members and 8 returning participants from various colleges across the United States.
The company hosted its first-ever Dexcom U Signing Day Camp in Baltimore, featuring Baltimore Ravens tight end Mark Andrews and NFL legend Mike Golic Sr. The program, launched in 2022, has impacted over 40 college athletes across 38 schools and 19 sports. All participants use Dexcom's continuous glucose monitoring (CGM) technology to manage their diabetes while competing at the collegiate level.
DexCom (NASDAQ:DXCM) has scheduled its second quarter 2025 earnings release and conference call for July 30, 2025. The company will release its financial results after market close, followed by a management conference call at 4:30 p.m. Eastern Time to review the quarterly performance.
Investors can access the conference call by dialing (888) 414-4585 (US/Canada) or (646) 960-0331 (International) using confirmation ID "9430114". A concurrent webcast will be available on the Dexcom investor relations website at investors.dexcom.com, where it will also be archived for future reference.
FAQ
What is the current stock price of Dexcom (DXCM)?
What is the market cap of Dexcom (DXCM)?
